Verano (OTCMKTS:VRNOF – Get Free Report) and Trinity Biotech (NASDAQ:TRIB – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.
Insider and Institutional Ownership
9.0% of Verano shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 9.1% of Verano shares are owned by company insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Verano and Trinity Biotech, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Verano | 1 | 0 | 0 | 0 | 1.00 |
| Trinity Biotech | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Verano and Trinity Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Verano | -41.68% | -9.54% | -4.51% |
| Trinity Biotech | N/A | N/A | N/A |
Valuation and Earnings
This table compares Verano and Trinity Biotech”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Verano | $878.59 million | 0.52 | -$341.86 million | ($0.98) | -1.29 |
| Trinity Biotech | $43.78 million | 0.13 | -$35.98 million | ($44.26) | -0.16 |
Trinity Biotech has lower revenue, but higher earnings than Verano. Verano is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Verano has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.
Summary
Trinity Biotech beats Verano on 6 of the 11 factors compared between the two stocks.
About Verano
Verano Holdings Corp. operates as a vertically integrated multi-state cannabis operator in the United States. The company engages in the cultivation, processing, wholesale, and retail distribution of cannabis in Arizona, Arkansas, Connecticut, Florida, Illinois, Maryland, Massachusetts, Michigan, Nevada, New Jersey, Ohio, Pennsylvania, and West Virginia. It offers cannabis products under the Encore, Avexia, MUV, Savvy, BITS, and Verano brands for medical and adult-use markets. The company is headquartered in Chicago, Illinois.
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Receive News & Ratings for Verano Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verano and related companies with MarketBeat.com's FREE daily email newsletter.
